These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Surfactant replacement therapy: issues related to currently available preparations. Bose G Neonatal Netw; 1992 Jun; 11(4):vii-xii. PubMed ID: 1608367 [No Abstract] [Full Text] [Related]
5. Hyaline membrane disease (HMD) therapy in Latin America: impact of exogenous surfactant administration on newborn survival, morbidity and use of resources. Rossello JD; Hayward PE; Martell M; Del Barco M; Margotto P; Grandzoto J; Bastida J; Peña J; Villanueva D J Perinat Med; 1997; 25(3):280-7. PubMed ID: 9288665 [TBL] [Abstract][Full Text] [Related]
6. The physiologic effects of surfactant treatment on gas exchange in newborn premature infants with hyaline membrane disease. Cotton RB; Olsson T; Law AB; Parker RA; Lindstrom DP; Silberberg AR; Sundell HW; Sandberg K Pediatr Res; 1993 Oct; 34(4):495-501. PubMed ID: 8255684 [TBL] [Abstract][Full Text] [Related]
7. Single dose surfactant rescue therapy in neonatal respiratory distress syndrome. Sanghvi KP; Merchant RH Indian Pediatr; 1998 Jun; 35(6):533-6. PubMed ID: 10216648 [No Abstract] [Full Text] [Related]
8. [Natural or synthetic surfactant in the treatment of neonatal respiratory distress syndrome]. Robertson B; Sangstad OD Tidsskr Nor Laegeforen; 1994 Feb; 114(5):590-1. PubMed ID: 8209345 [No Abstract] [Full Text] [Related]
9. Surfactant replacement therapy in neonates less than 32 weeks gestation: effect on neonatal intensive care resource utilization. Diwaker K; Roberts S; John E J Paediatr Child Health; 1993 Dec; 29(6):434-7. PubMed ID: 8286159 [TBL] [Abstract][Full Text] [Related]
11. Differences in immediate and short-term outcome of premature neonates treated with two types of exogenous surfactant preparation. Malathi I; Ng KC Ann Acad Med Singap; 1995 Nov; 24(6):781-4. PubMed ID: 8838980 [TBL] [Abstract][Full Text] [Related]
12. Costs and outcomes associated with colfosceril versus beractant for the treatment of neonatal respiratory distress syndrome. Wyble L; Santeiro ML Ann Pharmacother; 1997 Jun; 31(6):787-8. PubMed ID: 9184726 [No Abstract] [Full Text] [Related]
13. Cerebral blood flow velocity after surfactant instillation in preterm infants. van de Bor M; Ma EJ; Walther FJ J Pediatr; 1991 Feb; 118(2):285-7. PubMed ID: 1993962 [No Abstract] [Full Text] [Related]
15. [The effect of surfactant therapy on the oxygen treatment of premature infants with HMD]. Iarŭkova N Akush Ginekol (Sofiia); 1998; 37(1):3-5. PubMed ID: 9770786 [TBL] [Abstract][Full Text] [Related]
16. Respiratory mechanics before and after late artificial surfactant rescue. Todd DA; Choukroun ML; Fayon M; Kays C; Guénard H; Galpérine I; Demarquez JL J Paediatr Child Health; 1995 Dec; 31(6):532-6. PubMed ID: 8924306 [TBL] [Abstract][Full Text] [Related]
17. Retinopathy of prematurity in infants less than 29 weeks' gestation: 3 1/2 years pre- and postsurfactant. Kennedy J; Todd DA; Watts J; John E J Pediatr Ophthalmol Strabismus; 1997; 34(5):289-92. PubMed ID: 9310917 [TBL] [Abstract][Full Text] [Related]
18. Exosurf versus Survanta surfactant preparations: proportional-hazards regression analysis of time to successful extubation and discontinuation of oxygen therapy. Arnold C; Adams E; Torres E; Sidebottom R J Perinatol; 1996; 16(1):9-14. PubMed ID: 8869533 [TBL] [Abstract][Full Text] [Related]
19. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Phibbs RH; Ballard RA; Clements JA; Heilbron DC; Phibbs CS; Schlueter MA; Sniderman SH; Tooley WH; Wakeley A Pediatrics; 1991 Jul; 88(1):1-9. PubMed ID: 2057244 [TBL] [Abstract][Full Text] [Related]